The test, developed with Pfizer, could identify renal cancer patients who would experience recurrence, but not who would benefit from adjuvant Sutent.
The company is testing the assay's potential as a tool to manage the treatment of patients with primary breast cancer.
The US National Institute of Mental Health has funded fewer clinical trials since it began to emphasize studies of the biological basis of disease, Nature News reports.
A new analysis has uncovered clinical trial papers that have reported suspicious data, the Guardian reports.
There are now 100 sites in the US participating in the basket study, and soon trials with similar approaches will be available in Canada and 13 other countries.
Data presented at ASCO showing 76 percent of cancer patients responded to larotrectinib could lead to the availability of the first tissue-agnostic targeted drug.
Clinical embryonic stem cell trials are set to begin in China, according to Nature News.
Collaborators have created an atlas that compares available PD-L1 IHC assays and reveals areas of debate, including challenges encountered by clinicians.
Researchers in China have begun another trial using CRISPR/Cas9 approaches in cancer patients, according to the Wall Street Journal.
The company presented data demonstrating that ADHD patients with mutations in nine genes had a clinically meaningful and statistically significant response to AEVI-001.
In a cartoon, Vox explores the lack of women among this year's winners of the Nobel Prize.
Science reports a new US defense bill would establish two groups aimed at combating foreign influence on research.
Nature Biotechnology discusses promising early results from two clinical trials of CRISPR-based therapy for β-thalassemia and sickle cell disease.
In Cell this week: analysis of tissue clones, metagenomic studies of ocean water samples, and more.